UroGen Pharma is a clinical-stage biopharmaceutical company focused on developing advanced, innovative treatments to address unmet needs in the field of urology, with a focus on uro-oncology. UroGen has developed RTGel™, a novel technology platform designed to facilitate minimally invasive intracavitary treatment of challenging urologic conditions.
RTGel is designed to increase the dwell time and exposure of active drugs, potentially increasing the viability of organ-sparing techniques.
UroGen’s lead investigational candidates, UGN-101 (mitomycin gel) for instillation, and UGN-102 (mitomycin gel) for intravesical instillation, are designed to ablate tumors while avoiding radical surgeries, and are currently being investigated in several forms of non-muscle invasive urothelial cancer, including low-grade upper tract urothelial and bladder cancer, respectively. UroGen Pharma is headquartered in New York, NY with operations in Los Angeles, CA, and Israel. UroGen Pharma is composed of the parent company UroGen Pharma Ltd., and UroGen Pharma Inc.